THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
AROUND THE REGION

Sanofi changes Genzyme reporting

By Robert Weisman
Globe Staff / June 1, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

French drug maker Sanofi SA yesterday told employees of Genzyme Corp., the Cambridge company Sanofi acquired in April, that they will have a new reporting structure within the parent company.

Sanofi chief executive Christopher A. Viehbacher said earlier this year that Genzyme will retain its name and remain a standalone biotechnology unit within Sanofi.

But in an employee bulletin out yesterday, Sanofi said the Genzyme unit will be smaller and include only its personalized genetic health and multiple sclerosis operations.

Genzyme’s current oncology, biosurgery, and renal operations will be integrated into Sanofi businesses, the new owner said. Sanofi did not say if that move would involve job cuts. Genzyme currently employs about 4,500 workers in Massachusetts and 10,000 worldwide.

Sanofi said Viehbacher will continue as acting Genzyme chief executive until September, when a new Genzyme chief executive will be named.